middle.news
Amplia’s Pancreatic Cancer Drug Shows 35% Response Rate, FDA Backs Dose Plan
8:50am on Friday 30th of January, 2026 AEDT
•
Healthcare
Read Story
Amplia’s Pancreatic Cancer Drug Shows 35% Response Rate, FDA Backs Dose Plan
8:50am on Friday 30th of January, 2026 AEDT
Key Points
35% confirmed partial response rate in ACCENT trial surpasses chemotherapy alone
Phase 1b/2a AMPLICITY trial combining narmafotinib with FOLFIRINOX underway
Positive FDA feedback supports dose optimisation without delaying development
Key patent granted extending narmafotinib protection to 2040
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Amplia Therapeutics (ASX:ATX)
OPEN ARTICLE